Gilead will buy Corus Pharma ... | Chemical & Engineering News
Volume 84 Issue 30 | p. 17 | Concentrates
Issue Date: July 24, 2006

Gilead will buy Corus Pharma ...

Department: Business

Gilead Sciences intends to exercise its option to acquire Corus Pharma for $365 million. Gilead invested $25 million in Corus in April, becoming the firm's second largest shareholder and gaining the option to buy the rest of the company. Other investors in Corus, which is developing respiratory and infectious disease products, include several investment banks.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment